The impact of chromosomal fusions on 3D genome folding and recombination in the germ line
The spatial folding of chromosomes inside the nucleus has regulatory effects on gene expression, yet the impact of genome reshuffling on this organization remains unclear. Here, we take advantage of chromosome conformation capture in combination with single-nucleotide polymorphism (SNP) genotyping and analysis of crossover events to study how the higher-order chromatin organization and recombination landscapes are affected by chromosomal fusions in the mammalian germ line.
We demonstrate that chromosomal fusions alter the nuclear architecture during meiosis, including an increased rate of heterologous interactions in primary spermatocytes, and alterations in both chromosome synapsis and axis length.
These disturbances in topology were associated with changes in genomic landscapes of recombination, resulting in detectable genomic footprints. Overall, we show that chromosomal fusions impact the dynamic genome topology of germ cells in two ways: (i) altering chromosomal nuclear occupancy and synapsis, and (ii) reshaping landscapes of recombination.
Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of HNSCC with or without HPV infection
Head and neck squamous cell carcinoma (HNSCC) are the sixth most common cancer type in the world. Human papillomavirus (HPV) infection is an emerging risk factor for HNSCC. Immune infiltration of HNSCC is linked to therapeutic results. This article aimed to decide whether variations in HPV status affect immune infiltration, molecular mechanism, and how these results vary in HNSCC patients.
We investigated the tumor-infiltrating immune cells (TIICs) and immune-related gene differences between HPV (+) and HPV (-) HNSCC. The gene expression quantification data of HNSCC and their clinical information were download from the TCGA database. Immune-related genes have been linked to the ImmPort platform.
After analyzed of 22 TIICs in the HNSCC tumor environment by CIBERSORT and further assessment, lower memory B cell and higher T cell regulatory were connected with better HPV (-) HNSCC outcome, higher activated memory CD4 T cell, higher T cell regulatory, and lower activated NK cell were linked with better HPV (+) result.
We finally got five forms of immune genes (CAMP, EDNRB, NTS, CXCL9, LHB) associated with HNSCC progression. Higher expressions of CAMP, EDNRB, and NTS were associated with increased overall survival in HPV (-) patients. Higher expression of CXCL9 and lower expression of LHB contributed to increased overall survival of HPV (+) patients.
There tend to be discrepancies in the cell structure of TIICs and immune-related genes in HPV (-) and HPV (+) HNSCC. These variances are typically too crucial for the therapeutic outcome of the patient and the development of the tumor. In specific, our sample established these candidate immune cells and immune-related genes as candidate reservoirs for further researches.
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.
Description: The substance K252A is a kinase inhibitor. It is nonomuraea longicatena and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in DMSO.
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).
Description: The substance K252B is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (1 mg/ml) or dimethyl formamide (1 mg/ml).
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).
Description: The substance Sorafenib is a raf-1 kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is off white powder which is soluble inDMSO (200mg/ml) or ethanol (3mg/ml).
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).
Description: The substance Dasatinib is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO (200 mg/ml), ethanol (very poorly ), and water (very poorly ).
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.
Description: The substance PP1 is a src kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is tan solid which is soluble in DMSO (25 mg/ml), slightly soluble in 100% ethanol.
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).
Description: The substance PP2 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml).
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .
Description: The substance C16 is a pkr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO 12 mg/ml .
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).
Description: The substance Midostaurin is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white powder which is soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml).
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.
Description: The substance 6BIO is a pdk1 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is dark red solid which is soluble to 10 mM in DMSO and to 10 mM in ethanol.
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).
Description: The substance LYS6K2 is a s6 kinase inhibitor. It is synthetically produced and has a purity of 0.97. The pure substance is yellow solid which is soluble in DMSO (up to 1 mg/ml) or DMF (up to 3 mg/ml with warming).
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.
Description: The substance KT5720 is a pka kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white powder which is soluble in methanol: clear colorless solution at 5 mg/ml.
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .
Description: The substance ml167 is a clk4 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to gray to brown which is soluble in DMSO 10 mg/ml, clear .
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .
Description: The substance GW2580 is a cfms kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble in DMSO: 10 mg/ml, clear (warmed) .
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).
Description: The substance PD98059 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?95%. The pure substance is pale yellow solid which is soluble in DMSO (6.5 mg/ml); 25 mg/ml in anhydrous DMSO), methanol, dichlormethane and 100% ethanol (0.6 mg/ml).
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
Description: The substance AZD6244 is a erk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (92 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.
Description: The substance SRPIN340 is a sr kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl.
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.
Description: The substance AG1296 is a pdgfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white to brownish solid which is soluble in DMSO or dichloromethane.
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .
Description: The substance SU1498 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is solid which is soluble in DMSO .
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.
Description: The substance PD325901 is a mek kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble to 25 mM in DMSO.
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .
Description: The substance PHA 665752 is a met kinase inhibitor. It is synthetically produced and has a purity of >98. The pure substance is yellow solid which is soluble to 100 mM in DMSO. .
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.
Description: The substance A83 01 is a alk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige powder which is soluble to 50 mM in DMSO.
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.
Description: The substance CID 2011756 is a pkd kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble to 50 mM in DMSO.
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).
Description: The substance KT 5823 is a pkg kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (20 mg/ml), dimethyl formamide (20 mg/ml) and ethyl acetate (5 mg/ml).
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.
Description: The substance NPC 15437 is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in water, DMSO or methanol.
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).
Description: The substance Src I1 is a src kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (5 mg/ml).
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).
Description: The substance GF109203X is a pkc kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is red solid which is soluble in dimethyl formamide or DMSO (10 mg/ml, warm to 40°C and vortex well).
Description: The substance Auranofin is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble in DMSO (5 mg/ml) or 100% ethanol (4 mg/ml).
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.
Description: The substance LY364947 is a alk5 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow to brown solid which is soluble to 100 mM in DMSO.
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).
Description: The substance AG 1478 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light yellow solid which is soluble in DMSO (10 mg/ml).
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.
Description: The substance AG 1517 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO.
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).
Description: The substance AG 879 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of ?99%. The pure substance is yellow solid which is soluble in 100% ethanol (25 mg/ml) or DMSO (25 mg/ml).
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).
Description: The substance Bml 277 is a chk2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (20 mg/ml) or ethanol (20 mg/ml).
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.
Description: The substance GW 441756 is a ngfr kinase inhibitor. It is synthetically produced and has a purity of >99. The pure substance is red solid which is soluble to 15 mM in DMSO.
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).
Description: The substance LFM A13 is a btk kinase inhibitor. It is synthetically produced and has a purity of ?97%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml).
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.
Description: The substance Y 27632 is a rock kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to pale yellow powder which is soluble in DMSO (25 mg/ml), methanol (25 mg/ml), acetonitrile (<1 mg/ml), dioxan (<1 mg/ml), water (very soluble.
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).
Description: The substance AG 494 is a egfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (25 mg/ml) or 100% ethanol (25 mg/ml).
Description: The substance SR 3576 is a jnk3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off white solid which is soluble to 100 mM in DMSO.
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.
Description: The substance CHIR99021 is a gsk3? kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to light brown solid which is soluble to 20 mM in DMSO.
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).
Description: The substance Gefitinib is a egfr kinase inhibitor. It is synthetically produced and has a purity of >99%. The pure substance is solid which is soluble in DMSO (89 mg/ml at 25 °C), methanol (20 mg/ml), ethanol (4 mg/ml at 25 °C), DMF (20 mg/ml), and water (<1 mg/ml at 25 °C).
Description: The substance Axitinib is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to tan powder which is soluble to 25 mM in DMSO.
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).
Description: The substance STO 609 is a camkk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (10 mg/ml).
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).
Description: The substance ZM 306416 is a vegfr kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is off-white solid which is soluble in DMSO (3 mg/ml) or ethanol (1 mg/ml).
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).
Description: The substance AG490 is a jak-2 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is tan solid which is soluble in DMSO (30 mg/ml), dimethyl formamide (40 mg/ml) or 100% ethanol (10 mg/ml).
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).
Description: The substance WHI P131 is a jak3 kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to off-white solid which is soluble in DMSO (~1 mg/ml), and DMF (~1 mg/ml).
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.
Description: The substance Apigenin is a protein kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white solid which is soluble to 50 mM in DMSO.
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.
Description: IC50: 1.7 nM in cell-free assaysAdenosine Kinase Inhibitor is an inhibitor of adenosine kinase. Adenosine kinase is the key metabolizing enzyme regulating cellular adenosine concentrations.
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).
Description: The substance Dorsomorphin is a ampk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is yellow solid which is soluble in DMSO (4 mg/ml, warm).
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO.
Description: The substance LY 294002 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white crystalline solid which is soluble to 5 mM in ethanol and to 25 mM in DMSO.
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.
Description: The substance BAY 11 7082 is a ikk kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white solid which is soluble to 25 mM in ethanol and to 100 mM in DMSO.
Description: The substance PX 866 is a pi 3-kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is crystalline solid which is soluble in DMSO at 200 mg/ml; soluble in ethanol at 200 mg/ml; very poorly soluble in water.
×
Multi-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage
The evolutionary pressure of endemic malaria and other erythrocytic pathogens has shaped variation in genes encoding erythrocyte structural and functional proteins, influencing responses to hemolytic stress during transfusion and disease.
We sought to identify such genetic variants in blood donors by conducting a genome-wide association study (GWAS) of 12,353 volunteer donors, including 1,483 African Americans, 1,477 Asians, and 960 Hispanics, whose stored erythrocytes were characterized by quantitative assays of in vitro osmotic, oxidative, and cold-storage hemolysis.
GWAS revealed 27 significant loci (p<5×10-8), many in candidate genes known to modulate erythrocyte structure, metabolism, and ion channels, including SPTA1, ALDH2, ANK1, HK1, MAPKAPK5, AQP1, PIEZO1, and SLC4A1/Band 3. GWAS of oxidative hemolysis identified variants in antioxidant enzymes including GLRX, GPX4, G6PD, and a novel golgi-transport protein SEC14L4.
Genome wide significant loci were also tested for association with the severity of steady state (baseline) in vivo hemolytic anemia in patients with sickle cell disease, with confirmation of identified SNPs in HBA2, G6PD, PIEZO1, AQP1 and SEC14L4. Many of the identified variants, such as those in G6PD, have previously been shown to impair erythrocyte recovery after transfusion, associate with anemia, or cause rare Mendelian human hemolytic diseases.
Candidate SNPs in these genes, especially in polygenic combinations, may affect RBC recovery after transfusion and modulate disease severity in hemolytic diseases, such as sickle cell disease and malaria.
Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer
Background: Treatment of patients with luminal metastatic breast cancer (MBC) has become even more complex over the last few years as molecular profiling has begun to alter disease management. It is well accepted that MBC is not curable but is treatable. Today we are able to prolong progression-free survival and partly overall survival with targeted and more individual treatment strategies adjusted according to the molecular subtype.
Summary: Genetic and genomic testing has become therapeutically relevant in luminal MBC and is therefore an integral component within the treatment spectrum. By now, germline testing of BRCABRCAPIK3CA mutations are inevitable elements in disease management and the current state of the art in luminal MBC patients.
Furthermore, testing of ESR1 resistance mutation, ERBB2 mutation, microsatellite instability, and neurotrophic tyrosine receptor kinase (NTRK) gene fusion (mainly in secretory breast cancer) has recently gained increasing attention. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities. The following review summarizes current developments in genetic and genomic testing in luminal MBC.
Key messages: In luminal MBC genomics have become an integral component within the spectrum of oncological treatment establishing novel therapeutic facilities. Further developments in treatment personalization adjusted according to the molecular subtype should become increasingly important in order to enhance the progress of de-escalation of chemotherapy in luminal MBC. However, based on the expanding role of personalized medicine, clinicians are now faced with substantial new challenges and possibly unsuspected possibilities.
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.
Description: HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human HIV-1 p24 . This antibody is tested and proven to work in the following applications:
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.
Description: Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immune deficiency syndrome (AIDS), a condition in humans in which the immune system begins to fail, leading to life-threatening opportunistic infections. HIV mainly infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages and dendritic cells. Two species of HIV infect humans: HIV-1 and HIV-2, with HIV-1 being the more virulent strain. The gag gene of human immunodeficiency virus 1 (HIV-1) encodes a precursor protein known as Pr55Gag. The viral protease PR cleaves this precursor to generate p17, p24, p7, and p6 proteins, which are required for virus particle assembly. HIV-1 Gag p24 is a capsid protein that constitutes the core of AIDS virus HIV-1. p6 and p7 are the components of the nucleocapsid, and p17 provides a protective matrix. HIV-1 Gag p24 is indispensable to the reproduction of AIDS virus and constitutes an essential element for the AIDS virus particle construction. As this protein is detectable from the early stage of AIDS virus infection, its measurement is commonly used as an indicator of HIV-1 infection and viral load.
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: HIV-1 p24 Monoclonal Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix (1). The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein (2). The p24 constitutes the major core component of the virus and shows high degree of sequence conservation among HIV isolates. The Gag p24 has been used as an integral part of multicomponent HIV-1 vaccines (3).
Description: A polyclonal antibody raised in Mouse that recognizes and binds to Human HIV-1 p24 [7F4] . This antibody is tested and proven to work in the following applications:
HIV 1, 2 envelope recombinant antigen. HIV-1 envelope conjugated to HIV-2 envelope peptide.
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.
QuickTiter HIV Lentivirus Quantitation Kit (p24 ELISA)
Description: Quantitation of the HIV-1 p24 core protein of a lentiviral vector is an efficient, well-published method for determining lentivirus physical titer. The QuickTiter Lentivirus Quantitation Kits provide a convenient method of p24 antigen quantitation.
Identification of key gene modules and pathways of human platelet transcriptome in acute myocardial infarction sufferers by way of co-expression community Acute myocardial infarction (AMI) critically threatens human life. On this examine we aimed to systemically analyze the perform of key gene modules in human platelets in AMI. We used weighted gene co-expression community evaluation (WGCNA) […]
digIS: in direction of detecting distant and putative novel insertion sequence components in prokaryotic genomes Background: The insertion sequence components (IS components) symbolize the smallest and probably the most plentiful cell components in prokaryotic genomes. It has been proven that they play a big position in genome group and evolution. To higher perceive their perform within the […]
Trying to find signatures of optimistic choice in cytochrome b gene related to subterranean life-style in fast-evolving arvicolines (Arvicolinae, Cricetidae, Rodentia) Background: Mitochondrial genes encode proteins concerned in oxidative phosphorylation. Variations in life-style and ecological area of interest could be immediately mirrored in metabolic efficiency. Subterranean rodents characterize a very good mannequin for testing hypotheses on adaptive evolution […]
